Myelodysplastic Syndrome

Myelodysplastic syndromes (MDS) are a group of bone marrow cancers in which early blood forming cells (blasts) fail to mature into healthy red blood cells, white blood cells, and/or platelets. As a result, people develop cytopenias (low blood counts) that can cause anemia, infections, or bleeding; in some cases, MDS can progress to acute myeloid leukemia (AML).

Understanding MDS

In healthy marrow, stem cells gradually mature into normal blood cells. In MDS, abnormal stem cells do not mature properly; many die in the marrow or soon after entering the blood. That leaves too few functional cells and explains the hallmark problems of anemia (low red cells), neutropenia (low white cells), and thrombocytopenia (low platelets).

Doctors diagnose specific MDS subtypes based on blood/marrow appearance, blast percentage, cytogenetics, and other features (per WHO/ICC era classifications), because these details help guide prognosis and treatment.

Signs & Symptoms

Fatigue, shortness of breath, pallor (from anemia)
Easy bruising/bleeding, petechiae (from thrombocytopenia)
Frequent infections or slow healing (from neutropenia)

Some people are identified through abnormal blood tests before symptoms appear.

Risk Factors

Older age (MDS is most common ≥60–70 years)
Prior chemotherapy or radiation for another cancer (therapyrelated MDS)
Rare environmental exposures (e.g., certain chemicals) and less commonly, inherited predisposition syndromes

Having a risk factor does not mean someone will develop MDS; many people with MDS have no identifiable cause.

Screening

There is no routine screening for MDS. Evaluation is triggered by unexplained cytopenias or suggestive symptoms, followed by specialized testing.

Diagnosis

A thorough diagnostic workup typically includes:

(CBC with differential) and peripheral smear to document cytopenias and assess cell morphology.

with cytogenetic/molecular testing to confirm MDS, define subtype, and assess risk.

as needed to exclude other causes of cytopenias and to plan therapy.

Risk Stratification & Progression

Doctors classify MDS as lower risk or higher risk using validated systems that incorporate blast percentage, cytopenias, and cytogenetics—because these factors predict the likelihood of complications and transformation to AML and help tailor therapy intensity.

Treatment Overview

Care is individualized based on risk category, symptoms, marrow/genetic features, overall health, and your goals.

Observation/Watchful Waiting (selected lower risk cases)

For smoldering myeloma without organ damage, many patients are monitored closely; selected high risk smoldering cases may be offered clinical trials or early intervention strategies.

Supportive & SymptomDirected Care

Transfusions (red cells/platelets) to relieve symptoms and prevent complications; iron chelation may be used for transfusionrelated iron overload.
Growth factors (e.g., erythropoiesisstimulating agents) for anemia in selected patients; infection prevention and prompt treatment remain essential with neutropenia.

DiseaseModifying Therapies

Hypomethylating agents (e.g., azacitidine or decitabine) can improve counts, reduce transfusion needs, and delay progression in many patients.
Targeted approaches for defined subgroups, such as therapies for isolated del(5q), may be considered based on marrow/cytogenetic findings and current guidelines.

Stem Cell Transplant (Allogeneic HSCT)

For eligible patients—especially those with higherrisk disease—allogeneic stem cell transplant offers the only potentially curative option, balancing potential benefit with transplant risks.

Relapsed/Refractory MDS & Clinical Trials

If disease persists or returns, your team will review additional drug options, consider clinical trials, and reevaluate transplant candidacy as appropriate. Because MDS research is rapidly evolving, trial participation can provide access to promising therapies. Current Clinical Trials – Illinois CancerCare

Good to know: NCCN patient guidelines offer detailed, lay-friendly algorithms for lower risk vs higher risk MDS, including when to consider HMAs, transplant, and clinical trials—your team can walk you through how these apply to you.

Prognosis

Outcomes vary widely. Prognosis is driven by blast percentage, cytogenetics/molecular features, and the number/severity of cytopenias; many people live for years with careful monitoring and individualized treatment, while higherrisk cases may progress more quickly without diseasemodifying therapy. Your doctor will explain what your specific features mean.

Follow-Up & Supportive Care

After diagnosis (and throughout treatment), followup typically includes:

Regular visits with CBCs and periodic marrow or molecular assessments as indicated.
Ongoing infection prevention, transfusion planning, and management of symptoms/side effects (including iron overload prevention when needed).
Personalized counseling on vaccinations, activity/nutrition, and when to call for new symptoms.

Why Choose Illinois CancerCare

Experienced hematology team with up-to-date diagnostics, risk-adapted care pathways, and access to supportive services close to home.
Clinical trials: We participate in research studies for MDS and related marrow disorders; when helpful, we coordinate referrals to regional transplant and specialty centers. Current Clinical Trials – Illinois CancerCare

Sources & Patient Friendly References

All information was taken from the NCI (National Cancer Institute) and ACS (American Cancer Society).